Bextra withdrawal dents Pfizer’s sales juggernaut
April 22, 2005Sales and Marketing
The suspension and withdrawal of Pfizer's Cox-II inhibitor Bextra has forced the company to cut its profit forecast for 2005, …
PCT mergers won’t solve financial problems, warns report
April 19, 2005PCT mergers are unlikely to relieve the burden of financial pressures, according to a major report by the NHS Alliance.The …
US court rules in favour of Lilly’s Zyprexa
April 18, 2005Sales and Marketing
Lilly's US patent on blockbuster antipsychotic drug Zyprexa (olanzapine) has been upheld, after a Supreme Court ruled against its generic …
Labour makes clinical trials law a manifesto pledge
April 15, 2005Research and Development
The Labour party has promised to introduce new legislation which would oblige pharmaceutical companies to publish clinical trial data for …
Novartis signs respiratory deal with UK biotech companies
April 14, 2005Research and Development
Novartis has signed a deal with two UK biotech companies to develop and market a new treatment for chronic obstructive …
Ogilvy reshuffle sweetens Healthworld
April 14, 2005Medical Communications
The new Ogilvy Healthworld Advertising agency has been launched in the UK following a re-organisation at media communications giant WPP.The …
Eloxatin and Campto gain new NICE approval
April 13, 2005Sales and Marketing
NICE has recommended two more chemotherapy drugs for the first-line treatment of advanced colorectal cancer.The institute said that Sanofi-Aventis' Eloxatin …
Secrets of a youthful brand
April 12, 2005Sales and Marketing Pan Advertising, Teva, lilly
Today, more than ever before, the pharmaceutical industry is constantly being reminded that a blockbuster drug’s days are numbered and …
New depression treatment relieves sleep problems in patients
April 12, 2005Sales and Marketing
An innovative new depression drug has shown improved benefits over existing treatments, according to data presented by its manufacturer Servier.Valdoxan …
Serono hit by two late-stage failures
April 8, 2005Research and Development, Sales and Marketing
Serono has halted development of a late-stage psoriasis drug and stopped another trial for a new skin cancer drug.Both drugs …
‘Fundamental misconceptions’ in MP’s report, says industry
April 7, 2005The ABPI has broadly welcomed the recommendations of the Health Select Committee's investigation into the pharmaceutical industry but has singled …
No salesforce purge in Pfizer’s $4 billion cuts
April 7, 2005Sales and Marketing
Pfizer has set out a $4 billion cost cutting programme for the next three years in an attempt to return …
New hepatitis B treatment approved in US
April 6, 2005Sales and Marketing
Bristol-Myers Squibb has received US approval for its hepatitis B treatment Baraclude after a six-month priority review.Baraclude (entecavir) is BMS's …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
